To evaluate the therapeutic efficacy of panobinostat in ATRT, we cultured a panel of human SMARCB1-deficient ATRT cell lines (BT12, BT16, CHLA04, CHLA05, CHLA06 and CHLA266) belonging to the ATRT-SHH and ATRT-MYC molecular subgroups and a neural stem cell (NSC) control cell line with intact SMARCB1 (Figure 1a, Supplementary Figure S7) in increasing concentrations of panobinostat. The gene discussed is SMARCB1; the disease is atypical teratoid rhabdoid tumor.